Home / Peptides / CJC-1295 + ipamorelin

CJC-1295 and ipamorelin

Not FDA-approved A popular growth-hormone stack that has never been tested as a combination in humans.

Short answer: both peptides make the pituitary release more growth hormone, through two different receptors. CJC-1295 raised GH and IGF-1 in a small 2006 study; ipamorelin failed its only phase 2 trial. No human trial has tested them together, there is no established dose, and neither can be legally compounded in the US.

Side by side

CJC-1295Ipamorelin
What it isLong-acting GHRH analogue (with DAC, binds albumin)Five-amino-acid ghrelin-receptor agonist
How it raises growth hormoneActs like the body's growth-hormone-releasing hormoneActs like ghrelin, a different trigger for GH release
Half-lifeAbout 6-8 daysShort (given twice daily IV in its trial)
Best human data2006 study in healthy adults: GH up 2-10x for 6+ days, IGF-1 up 1.5-3x2014 phase 2 (114 patients after bowel surgery): no benefit over placebo
FDA approvalNoneNone
CompoundingNot allowed (no 503A category, not in the 2026 HHS policy)Not allowed; still on the 503B significant-risk list
Safety signal FDA notedIncreased heart rate, widespread blood vessel dilationSerious adverse events with IV use

What is actually known

Raising growth hormone is not the same as a proven benefit. The marketing claims for this stack (fat loss, muscle, sleep, recovery) have not been shown in controlled trials of these peptides.

No dose is given here on purpose. Online "protocols" for this stack are not based on human trials. If you already have a prescribed dose and a vial, the CJC-1295 andipamorelin calculators convert it to syringe units.

More: CJC-1295 · ipamorelin ·tesamorelin vs sermorelin (the approved GHRH option)

Questions

Why are CJC-1295 and ipamorelin used together?
They push growth hormone release through two different receptors: CJC-1295 mimics GHRH, ipamorelin mimics ghrelin. The idea is that the two add up. That reasoning is plausible, but the combination has never been tested in a published human trial.
What is the CJC-1295 and ipamorelin dose?
There is no established human dose for the combination or for either peptide on its own for any use. The only human dosing data are from single-peptide studies: CJC-1295 in healthy adults (2006) and IV ipamorelin after bowel surgery (2014), which did not work.
Is CJC-1295 with ipamorelin legal?
Neither peptide is FDA-approved, and neither can be compounded by US pharmacies: both nominations were withdrawn and neither is in the October 2026 HHS draft peptide policy. Products sold online as 'research chemicals' are not for human use.
What are the side effects of CJC-1295 and ipamorelin?
There are no controlled data on the combination. The FDA noted increased heart rate and widespread blood vessel dilation with CJC-1295, and serious adverse events with IV ipamorelin. Long-term effects of raising growth hormone and IGF-1 this way are unknown.
What is the difference between CJC-1295 with DAC and without DAC?
They are different molecules. CJC-1295 with DAC binds to albumin in the blood and lasts about a week. 'CJC-1295 no DAC' (mod GRF 1-29) is short-acting. The 2006 human study used the DAC version.

Sources

  1. Teichman et al. 2006: CJC-1295 prolonged GH and IGF-I in healthy adults. JCEM (PubMed)
  2. Beck et al. 2014: Ipamorelin in postoperative ileus, phase 2 (PubMed)
  3. FDA: 503A bulk drug substance categories (updated May 14, 2026, PDF)
  4. Federal Register 2026-22192: HHS draft enforcement discretion policy for 503A compounding of certain peptides (Oct 30, 2026)

Last checked 2026-11-16. How we pick and check sources: methodology.